SCHEMBL4072403

SCHEMBL4072403

O=C(O)CCCC(=O)N1CCc2ccccc2C1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.70
SMN1; SMN2 Q16637 3/20 0.70
TSHR P16473 1/20 0.70
HSD17B10 Q99714 1/20 0.70
HDAC3 O15379 1/20 0.69
HDAC1 Q13547 1/20 0.69
HDAC10 Q969S8 1/20 0.69
HDAC11 Q96DB2 1/20 0.69
ALDH1A1 P00352 6/20 0.63
MAPT P10636 3/20 0.63
LMNA P02545 1/20 0.63
NPSR1 Q6W5P4 1/20 0.63
GAA P10253 1/20 0.60
KDM4E B2RXH2 2/20 0.59
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58
NLRP3 Q96P20 1/20 0.58
NOTUM Q6P988 1/20 0.57
NPC1 O15118 3/20 0.56
RAB9A P51151 3/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3244156 0.92 HPGD (0.68) HPGDSMN1; SMN2TSHRHSD17B10HDAC3
SCHEMBL6580790 0.86 HDAC3 (0.71) HPGDSMN1; SMN2TSHRHSD17B10HDAC3
SCHEMBL9138101 0.86 HDAC3 (0.71) HPGDSMN1; SMN2TSHRHSD17B10HDAC3
SCHEMBL5389653 0.84 HPGD (0.70) HPGDSMN1; SMN2TSHRHSD17B10HDAC3
SCHEMBL6228768 0.84 HDAC3 (0.68) HPGDSMN1; SMN2TSHRHSD17B10HDAC3
SCHEMBL794685 0.83 HDAC3 (0.72) HPGDSMN1; SMN2TSHRHSD17B10HDAC3
SCHEMBL13059439 0.83 HDAC3 (0.67) HPGDSMN1; SMN2TSHRHSD17B10HDAC3
SCHEMBL13487712 0.83 HDAC3 (0.67) HPGDSMN1; SMN2TSHRHSD17B10HDAC3
SCHEMBL5385138 0.83 HDAC3 (0.67) HPGDSMN1; SMN2TSHRHSD17B10HDAC3
SCHEMBL5380082 0.83 HDAC3 (0.67) HPGDSMN1; SMN2TSHRHSD17B10HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP claimed
JP-2007536323-A 2007-12-13 JP claimed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
EP-1745010-A1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2007-01-24 EP claimed
WO-2005110974-A1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2005-11-24 WO claimed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP disclosed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed
EP-1745010-A1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2007-01-24 EP disclosed
WO-2005110974-A1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2005-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds PKD1, DDC, DPYD HPGD 96/4885SMN1; SMN2 1061/4885TSHR 4464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.